IGM Biosciences Announces Delisting from Nasdaq Following Merger Completion
IGM Biosciences Inc. has announced its delisting from Nasdaq following its acquisition by Concentra Biosciences, LLC, which was finalized on August 14, 2025. The company requested the delisting of its common stock, leading to the suspension of trading and the filing of a Notification of Removal from Listing with the SEC. IGM will also terminate the registration of its shares and suspend reporting obligations under the Securities Exchange Act of 1934, as it becomes a wholly-owned subsidiary of Concentra.
IGM Biosciences Inc. announced a regulatory change following its acquisition by Concentra Biosciences, LLC. As part of the merger finalized on August 14, 2025, IGM Biosciences requested the delisting of its common stock from The Nasdaq Stock Market. Subsequently, trading of the shares was suspended, and a Notification of Removal from Listing and/or Registration on Form 25 was filed with the SEC. The company also plans to terminate the registration of its shares and suspend reporting obligations under the Securities Exchange Act of 1934. This move follows the change in control, making IGM a wholly-owned subsidiary of Concentra Biosciences. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGM Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-180763), on August 14, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
